PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword

PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword

Despite recent discoveries and therapeutic advances in aggressive myeloid neoplasms, there remains a pressing need for improved therapies. For instance, in acute myeloid leukemia (AML), while most patients achieve a complete remission with conventional chemotherapy or the combination of a hypomethyl...

Full description

Bibliographic Details
Main Authors: Clifford M. Csizmar, Antoine N. Saliba, Elizabeth M. Swisher, Scott H. Kaufmann
Format: Article
Language:English
Published: MDPI AG 2021-12-01
Series:Cancers
Subjects:
PARP inhibitors
acute myeloid leukemia
myelodysplastic syndrome
myeloid neoplasms
secondary malignancies
DNA damage repair
Online Access:https://www.mdpi.com/2072-6694/13/24/6385

Internet

https://www.mdpi.com/2072-6694/13/24/6385

Similar Items